Clinical trials: Chimeric Antigen Receptor T-cell Therapy
Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
- Trial name
- NCT06346912
- Testing
- CD19-BAFF Targeted CAR T-cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Multiple Myeloma, Multiple Myeloma in Relapse
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or GPRC5D or both sequentially in the treatment of Relapsed/ Refractory…
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma, Refractory
- Trial name
- BAH2573 (NCT07032129)
- Testing
- BCMA/GPRC5D CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Essen Biotech
Relapsed/Refractory Multiple Myeloma
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM).
- Trial name
- NCT07760454
- Testing
- CT0596
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- UCARsgen Biotech Limited
B-cell Acute Lymphoblastic Leukemia, Lymphoblastic B-Cell Lymphoma
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
- Trial name
- NCT05333302
- Testing
- CD19 CAR-T-cells, Tocilizumab
- Where
- Belarus
- Volunteers
- 10 people
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
B-Cell Neoplasm
Vaccine Responsiveness After CAR-T Cell Therapy
This phase I trial will use the inactivated rabies virus vaccine to assess immune function in patients who previously underwent B cell targeted chimeric antigen receptor-modified T cell immunotherapy (CARTx).
- Trial name
- NCT04410900
- Testing
- Wistar Rabies Virus Strain PM-1503-3M Vaccine, Biospecimen Collection
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Autoimmune Diseases
A Study of CAR-T Cells Targeting Autoimmune Diseases
The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in patients with autoimmune disease.
- Trial name
- NCT06661811
- Testing
- CAR-T
- Where
- China
- Sponsor
- Beijing Boren Hospital
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
The investigators propose an early phase study defined as a phase I/II trial assessing safety, feasibility and efficacy of CLIC-1901 autologous anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) cells for participants with…
- Conditions
- Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- CLIC-01 (NCT03765177)
- Testing
- CLIC-1901
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Ottawa Hospital Research Institute
Central Nervous System Tumor, Pediatric, Glioma
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells that are lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and…
- Conditions
- Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma
- Trial name
- NCT03638167
- Testing
- EGFR806-specific chimeric antigen receptor (CAR) T cell
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Seattle Children's Hospital
Castration-Resistant Prostate Cancer (CRPC)
A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer
An exploratory clinical study evaluating the safety and efficacy of ACT#001 chimeric antigen receptor T-cell (CAR-T cell) local injection in the treatment of castration-resistant prostate cancer.
- Trial name
- NCT07240857
- Testing
- Intraprostatic or localized lesion injection of ACT#001-PSMA CAR-T cells under transrectal ultrasound (TRUS) guidance
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Lymphoma, B-Cell, CAR-T
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.
- Trial name
- NCT06210243
- Testing
- C752
- Where
- China
- Volunteers
- 2 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Large B Cell Lymphoma, CAR T Cell
Impact of Lymphodepletion Regimen on the Response to CAR T-cells in Patients With With Relapsed/Refractory Large B-cell Lymphoma
CAR T cells therapy has transformed the prognostic of relapsed/refractory large B cells lymphomas. Relapse however is still high and multiple causes have been studied.
- Trial name
- CARLYM (NCT06988085)
- Testing
- Blood sampling
- Volunteers
- 42 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL)
ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
This Phase 1, single centre, open label dose escalation study aims to identify a safe dose of third-generation anti-CD19 CAR T-cells (WZTL-002) in the treatment of patients with relapsed or refractory (r/r) B-cell Non Hodgkin…
- Conditions
- Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)
- Trial name
- ENABLE-1 (NCT04049513)
- Testing
- WZTL002-1 (1928T2z CAR-T cells), Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- Malaghan Institute of Medical Research
High-risk Plasma Cell Neoplasms
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
This is a single arm study to evaluate the safety and efficacy of CAR BCMA-CD70 CAR-T cell therapy for high-risk plasma cell neoplasms.
- Trial name
- NCT07416682
- Testing
- CAR BCMA-CD70-T cells, fludarabine and cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS
This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of patients with Multi-drug resistant SRNS
- Trial name
- NCT06842589
- Testing
- anti-CD19 CAR-T cells
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Lymphoblastic Leukemia, Acute Adult
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell…
- Trial name
- TBI-1501 (NCT03155191)
- Testing
- TBI-1501
- Where
- 11 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Takara Bio Inc.
Metastatic Castration-resistant Prostate Cancer
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
An open-label, multi-center, Phase 1/2 study to determine the safety, tolerability, and feasibility of dosing adult patients with mCRPC with genetically modified autologous T-cells (TmPSMA-02) engineered to express a CAR capable…
- Trial name
- NCT05489991
- Testing
- TmPSMA-02
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tceleron Therapeutics, Inc.
Leukemia
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
Gene transfer is a process in which the DNA (genetic material) of certain cells is changed. In this study, gene transfer will be performed on a type of white blood cell (called T cells) to recognize leukemia cells in the same…
- Trial name
- NCT02194374
- Testing
- ROR1R-CAR-T Cell Infusion, Fludarabine, Cyclophosphamide
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma , Cholangiocarcinoma
Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors
Objective to study the safety and preliminary efficacy of intratumoral injection of CAR-T cells in the treatment of advanced liver tumors.
- Trial name
- NCT04951141
- Testing
- anti-GPC3 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
HIV-1
Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection
To evaluate the safety of autologous CAR-T-cell therapy in individuals lived with HIV-1 infection, CAR T cells are infused after ex vivo expansion and transduction with lentiviral vectors encoding a broadly neutralizing HIV-1…
- Trial name
- TCTIWHI (NCT04863066)
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Beijing 302 Hospital
Melanoma
NG2 and DLL3 CAR-T Cells Targeting Melanoma
The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.
- Trial name
- NCT07193966
- Testing
- NG2 and DLL3 CAR-T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.